ClinicalTrials.gg
CompletedNCT06437847Updated Jan 17, 2025

Assessment of the Need to Use Short Cognitive Tests for French General Practitioners/Family Doctors

An observational study in Cognitive Disorder, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-17.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
481
Ages
18 Years and older
Sex
All
01

Study summary

The prevalence of cognitive disorders is constantly increasing, with 1.2 million patients affected in France in 2016. Dementia is currently the seventh leading cause of death. In the absence of available treatment, systematic screening is not recommended. However, cognitive evaluation is recommended to maintain a level of autonomy for the patient at home. Targeted screening is the responsibility of the general practitioner. The latest recommendations from the HAS (2011) highlight the use of the MMSE as a first-line approach, there are no recommendations regarding short tests. Early cognitive assessment is limited by the time required to perform the tests and the knowledge about the available tools. The Codex is a short test, its sensitivity (92%) and specificity (85%) place it among the most discriminatory scores. It is underutilized in France. The objective of this thesis is to assess the training needs of general practitioners in short tests.

02

Conditions studied

  • Cognitive Disorder

Keywords

  • Cognitive evaluation
  • Short Test
  • General Practitioners
  • Codex, Training
  • Formation
03

In context

Cognitive Dysfunction

3,930 studies on the registry are indexed under Cognitive Dysfunction; 1,114 are open to participants now.

This study's enrollment of 481 is above the median of 150 across 989 observational studies indexed under Cognitive Dysfunction.

Browse Cognitive Dysfunction studies →

Lead sponsor

Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 597 studies on the registry; 127 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

General practitioners of the AURA Region will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • General practitioners of the AURA Region, in activity, university supervisor or not, trained or not trained in geriatrics.

Exclusion criteria

Exclusion Criteria:

  • General practitioners with exclusive practices in pediatrics, gynecology, aesthetics, rehabilitation, and homeopathy.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
481 participants (actual)
Patient registry
No

Interventions

  • OtherQuestionnaire

    Questionnaire assessing the use of cognitive tests.

06

What researchers measure

Primary outcomes

  1. Quantitative questionnaire 1

    Assessment of the need to use short cognitive tests

    Time frame: Month : 1, 3, 6

Secondary outcomes

  1. Quantitative questionnaire 2

    Assessment of the expectation regarding a project of training general practitioners to use the Codex tool (Sum = 4 or 5: = CODEX normal ; Sum = 0, 1, 2 or 3 = CODEX abnormal)

    Time frame: Month : 1, 3, 6

07

Study locations

1 site
  • Chu de Saint-Etienne
    Saint-Etienne, 42055, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06437847
Responsible party
Sponsor
First posted
May 31, 2024
Start date
Jun 5, 2024
Primary completion
Dec 5, 2024
Completion
Dec 5, 2024
Last update
Jan 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion